Pulmatrix Inc
NASDAQ:PULM

Watchlist Manager
Pulmatrix Inc Logo
Pulmatrix Inc
NASDAQ:PULM
Watchlist
Price: 2.47 USD 4.22% Market Closed
Market Cap: 9m USD

Operating Margin
Pulmatrix Inc

-207 100%
Current
-16 303%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-207 100%
=
Operating Profit
-6.2m
/
Revenue
3k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Pulmatrix Inc
NASDAQ:PULM
9m USD
-207 100%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
258.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
211.4B GBP
24%
CH
Novartis AG
SIX:NOVN
208.6B CHF
33%
US
Merck & Co Inc
NYSE:MRK
260.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
143.3B USD
29%
No Stocks Found

Pulmatrix Inc
Glance View

Market Cap
9m USD
Industry
Pharmaceuticals

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is headquartered in Lexington, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2014-03-21. The company designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.

PULM Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-207 100%
=
Operating Profit
-6.2m
/
Revenue
3k
What is the Operating Margin of Pulmatrix Inc?

Based on Pulmatrix Inc's most recent financial statements, the company has Operating Margin of -207 100%.

Back to Top